Latest Market News

Lincoln Minerals has secured all necessary approvals to begin a targeted drilling campaign at its Minbrie Copper Project in South Australia, aiming to unlock significant copper and base metal potential.

Atomo Diagnostics stands to gain significantly as Lumos Diagnostics’ FebriDx test secures FDA CLIA waiver approval, vastly expanding its US market potential. This regulatory milestone triggers substantial contracted revenues and prompts Atomo to ramp up production.

The Star Entertainment Group has locked in a binding refinancing agreement with WhiteHawk Capital Partners, securing US$390 million to refinance existing debt and boost liquidity. This move aims to stabilise the company’s financial footing ahead of key regulatory approvals and asset sales.

Impact Minerals has raised A$2 million through a strategic placement to advance its High Purity Alumina project and explore new industrial minerals opportunities in Western Australia.

Beacon Minerals has completed the sale of its MacPhersons Reward project to Forrestania Resources, receiving $5 million in cash and a substantial equity stake in Forrestania. This deal positions Beacon to sharpen its focus on core assets like the Lady Ida project while maintaining exposure to MacPhersons through its new shareholding.

Shriro Holdings has introduced a new dividend policy aiming to distribute 20-30% of net profit after tax annually, balancing shareholder returns with capital needs. The Board retains discretion over payments, factoring in franking credits and strategic priorities.

Aroa Biosurgery has completed its Symphony randomised controlled trial, demonstrating improved healing rates for diabetic foot ulcers compared to standard care. The preliminary results pave the way for clinical adoption and potential US reimbursement.

RocketBoots has secured a significant A$3.3 million activation contract with a leading multinational retailer, marking the start of a global deployment phase that complements its existing SaaS agreement and promises near-term revenue growth.

Botanix Pharmaceuticals has successfully renegotiated its API supply agreement, deferring significant purchases to later years and strengthening its financial position ahead of Sofdra's market rollout.

Genetic Signatures is undertaking a major organisational restructure to cut costs by $5 million and sharpen its commercial focus, aiming to accelerate growth in its diagnostic product offerings.

Cynata Therapeutics has completed the 100-day primary evaluation period for its Phase 2 trial of CYP-001 in acute graft versus host disease, with results expected in June 2026. This milestone marks a critical step for the biotech’s lead cell therapy candidate in a condition with few effective treatments.

EML Payments has appointed Adam Olding as its Global CEO, marking a pivotal step in its EML 2.0 transformation and signalling strengthened leadership to drive growth. Concurrently, regulatory developments around its Australian banking licence application introduce new compliance dynamics.